Bioequivalence and Oral Drug Formulation Events
News Oct 20, 2014
Curtis & Coulter LLC, are under 3 weeks away from hosting their co-located Bioequivalence: Intersection Between Science & Regulatory Summit and Oral Drug Formulation Innovations Summit taking place on November 5-6 2014 at the Westin San Diego, CA.
November’s events are specifically designed to unify and assist drug development organizations in streamlining the bioequivalence testing process, as well as optimizing formulation development approaches for oral drug products. This will in turn have a positive knock-on effect on approval rates of much-needed future drug products.
“We are delighted that multiple leading players within the global life sciences community share this vision and are thrilled that attendees will be joining us in San Diego from as far afield as China, India, Taiwan, Czech Republic, Brazil, Germany and Italy” stated Mark Coulter, CEO of Curtis & Coulter LLC. “It’s good to know the global life science community is committed to unite and work towards overcoming bioequivalence and formulation development challenges in order to ensure that faster, safer, much-needed drug products are readily available” he added.
The two events will include key presentations from Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson amongst other leading drug development organizations. Additionally presenters will include the FDA, and a number of other global regulatory agencies.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE